Vimta Labs informs about outcome of board meeting

27 Jan 2023 Evaluate
Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, Vimta Labs has informed that it enclosed Standalone and Consolidated Unaudited Financial Results for the third quarter ended 31st December 2022, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company’s website, https://vimta.comlinvestors/financial-statements/. Abridged financials are being published in the newspapers.

The above information is a part of company’s filings submitted to BSE.

Vimta Labs Share Price

509.45 30.65 (6.40%)
24-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1486.35
Dr. Reddys Lab 5962.50
Cipla 1400.00
Zydus Lifesciences 933.40
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.